Phase III study finds initial nivolumab-based treatment halts melanoma progression

Bookmark and Share
Published: 31 May 2015
Views: 1772
Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Wolchok presents, at a press conference at ASCO 2015, findings from a randomised phase III trial indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone.

Read the news article and watch the video interview for more.